Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

about

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

Item

http://www.wikidata.org/entity/Q57816558

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Utility of nintedanib for seve ...... gle-center retrospective study

@en

Utility of nintedanib for seve ...... gle-center retrospective study

@nl

type

Item

label

Utility of nintedanib for seve ...... gle-center retrospective study

@en

Utility of nintedanib for seve ...... gle-center retrospective study

@nl

prefLabel

Utility of nintedanib for seve ...... gle-center retrospective study

@en

Utility of nintedanib for seve ...... gle-center retrospective study

@nl

P1476

Utility of nintedanib for seve ...... gle-center retrospective study

@en

P2093

Jiro Terada

http://www.w3.org/2001/XMLSchema#string

Jun Ikari

http://www.w3.org/2001/XMLSchema#string

Kenichi Suzuki

http://www.w3.org/2001/XMLSchema#string

Kenji Tsushima

http://www.w3.org/2001/XMLSchema#string

Koichiro Tatsumi

http://www.w3.org/2001/XMLSchema#string

Masashi Sakayori

http://www.w3.org/2001/XMLSchema#string

Mitsuhiro Abe

http://www.w3.org/2001/XMLSchema#string

P2860

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

Pirfenidone in idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

P304

3369-3375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S179427

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30349191

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

drug discovery

pulmonary fibrosis

P932

6186773

http://www.w3.org/2001/XMLSchema#string